The Journal of Nutrition

Omega-3s did not significantly cut major cardiovascular events

Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.

Paper by Jo Ann E. Manson, Shari S. Bassuk, Nancy R. Cook, +10 more authorsJulie E. Buring
Figure 1 from The Journal of Nutrition
Open the figure at full size
Figure 1. Manson et al.
Studied:
Randomized trial in 25,871 older U.S. men and women, median 5.3 years, against placebo (Placebo-controlled)
What changed:
Major cardiovascular events did not differ with omega-3 supplements versus placebo (hazard ratio 0.92)
The catch:
Only 1 gram daily was evaluated; higher-dose effects were not measured
In the record:
The 276th paper on Omega-3 fatty acids with results in people; 722 on record in all. Its result on myocardial infarction agrees with 8 of 11 other findings on record; 3 found no change.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Among 25,871 US men aged 50 or older and women aged 55 or older, VITAL tested omega-3 supplements in a randomized, placebo-controlled trial. Participants took 1 gram of marine omega-3 fatty acids daily or placebo for a median of 5.3 years.

The supplements did not significantly reduce major cardiovascular events—heart and blood vessel events—or total cancer incidence. They reduced heart attacks and repeat hospitalizations for heart failure. They were also associated with fewer confirmed or probable cases of autoimmune disease, in which the immune system attacks the body. The supplements did not reduce deaths from any cause. They were not associated with atrial fibrillation, an irregular heartbeat. For several outcomes, benefits were greater in Black participants and those with lower fish intake or cardiovascular risk factors.

Why it matters

For chronic disease prevention as people age, the authors did not support routine omega-3 supplementation in healthy adults. They said targeted supplementation for people with low fish intake and other select groups warranted consideration.

Caveats

The trial tested prevention in a general population not selected for elevated cardiovascular or cancer risk. Its findings do not cover men under 50 or women under 55.

Comments

Be the first to comment.

Omega-3 fatty acids is part of Bryan Johnson's Blueprint and Rhonda Patrick's supplement routineMore supplements

The paper

Omega-3 Fatty Acid Supplementation Has Coronary and Other Selective Health Benefits: Comprehensive Results from the VITamin D and OmegA-3 TriaL (VITAL)

Jo Ann E. Manson, Shari S. Bassuk, Nancy R. Cook, +10 more authorsJulie E. Buring

The Journal of Nutrition, Nov 2026

doi.org/10.1016/j.tjnut.2026.101941